JPMorgan Downgrades Alnylam Pharmaceuticals (ALNY) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
FBR Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
August 10, 2015 5:42 PM EDTFBR Capital initiates coverage on Alnylam Pharmaceuticals (NASDAQ: ALNY) with a Outperform rating and a price target of $180.00.
Analyst Christopher S. James, M.D. commented, "Given its remarkably deep, diverse, and advanced pipeline, we view Alnylam as the best RNAi play in the... More
Alnylam Pharma (ALNY) Misses Q2 EPS by 10c
August 6, 2015 4:03 PM EDTAlnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($0.85), $0.10 worse than the analyst estimate of ($0.75). Revenue for the quarter came in at $8.69 million versus the consensus estimate of $12.64 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
... More